.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Fish and Richardson
Federal Trade Commission
Accenture
Colorcon
Boehringer Ingelheim
Citi
Chinese Patent Office
Johnson and Johnson

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,559,188

« Back to Dashboard

Which drugs does patent 6,559,188 protect, and when does it expire?


Patent 6,559,188 protects STARLIX and is included in one NDA. There has been one Paragraph IV challenge on Starlix.

This patent has forty-two patent family members in thirty countries.

This patent has expired prematurely due to non-payment of maintenance fees. See details below.

Summary for Patent: 6,559,188

Title: Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
Abstract:The invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, which comprises nateglinide (I) ##STR1## or repaglinide and at least one other antidiabetic compound selected from the group consisting of thiazolidinedione derivatives (glitazones), sulfonyl urea derivatives and metformin for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of diseases, especially metabolic disorders and in particular type 2 diabetes and diseases and conditions associated with diabetes; to a composition, respectively, which comprises nateglinide and a pharmaceutically acceptable carrier and to a process of making such composition; the use of such combination or composition for the preparation of a medicament for the prevention, delay of progression or treatment of metabolic disorders; a method of prevention, delay of progression or treatment of diseases in warm-blooded animals; the use of such combination or composition for the cosmetic treatment of a mammal in order to effect a cosmetically beneficial loss of body weight; and to a method of improving the bodily appearance of a warm-blooded animal.
Inventor(s): Gatlin; Marjorie Regan (Hoboken, NJ), Ball; Michele Ann (Morris Plains, NJ), Mannion; Richard Owen (Mount Arlington, NJ), Karnachi; Anees Abdulquadar (Hillsborough, NJ), Guitard; Christiane (Hegenheim, FR), Allison; Malcolm (Basel, CH)
Assignee: Novartis AG (Basel, CH)
Application Number:09/663,264
Patent Claim Types:
see list of patent claims
Composition; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
NovartisSTARLIXnateglinideTABLET;ORAL021204-001Dec 22, 2000ABRXYesNo► Subscribe► Subscribe► SubscribeYUSE FOR TREATMENT OF DIABETES, PARTICULARLY TYPE 2 DIABETES
NovartisSTARLIXnateglinideTABLET;ORAL021204-002Dec 22, 2000ABRXYesYes► Subscribe► Subscribe► SubscribeYUSE FOR TREATMENT OF DIABETES, PARTICULARLY TYPE 2 DIABETES
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,559,188

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,878,749 Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,559,188

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China1635874► Subscribe
China1309380► Subscribe
China101002758► Subscribe
Colombia5200844► Subscribe
Czech Republic20011723► Subscribe
EcuadorSP003659► Subscribe
European Patent Office1212077► Subscribe
European Patent Office2011507► Subscribe
Finland20010683► Subscribe
France2798592► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
Teva
Fish and Richardson
Merck
Argus Health
Chinese Patent Office
Accenture
Express Scripts
Julphar
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot